FDA ap­proves Sanofi's fac­tor VI­II he­mo­phil­ia A drug

Sanofi nabbed an FDA ap­proval for its new he­mo­phil­ia A ther­a­py, efane­soc­tocog al­fa, on Wednes­day evening, ac­cord­ing to FDA doc­u­ments.

The new­ly ap­proved drug — which has the fac­tor VI­II fo­cus spelled out in­side its brand­ed name, Al­tuvi­i­io — works to re­place the miss­ing or de­fec­tive fac­tor VI­II in he­mo­phil­ia A in a once-week­ly treat­ment. It wasn’t im­me­di­ate­ly clear Thurs­day morn­ing how Sanofi plans to price the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER